PL3844147T3 - Związki chemiczne - Google Patents
Związki chemiczneInfo
- Publication number
- PL3844147T3 PL3844147T3 PL20816376.6T PL20816376T PL3844147T3 PL 3844147 T3 PL3844147 T3 PL 3844147T3 PL 20816376 T PL20816376 T PL 20816376T PL 3844147 T3 PL3844147 T3 PL 3844147T3
- Authority
- PL
- Poland
- Prior art keywords
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1916210.6A GB201916210D0 (en) | 2019-11-07 | 2019-11-07 | High purity tryptamines and methods of synthesis thereof |
GBGB1917320.2A GB201917320D0 (en) | 2019-11-28 | 2019-11-28 | Novel compounds |
GB2008303.6A GB2585978B (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions |
PCT/EP2020/081502 WO2021089872A1 (en) | 2019-11-07 | 2020-11-09 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3844147T3 true PL3844147T3 (pl) | 2022-07-18 |
Family
ID=75849570
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL20816376.6T PL3844147T3 (pl) | 2019-11-07 | 2020-11-09 | Związki chemiczne |
PL20816375.8T PL3873883T3 (pl) | 2019-11-07 | 2020-11-09 | Sposób syntezy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL20816375.8T PL3873883T3 (pl) | 2019-11-07 | 2020-11-09 | Sposób syntezy |
Country Status (18)
Country | Link |
---|---|
US (4) | US11643390B2 (pl) |
EP (3) | EP3873883B1 (pl) |
JP (3) | JP7423131B2 (pl) |
KR (2) | KR20230142817A (pl) |
CN (2) | CN114829341B (pl) |
AU (2) | AU2020381103B2 (pl) |
BR (1) | BR112022008919A2 (pl) |
CA (2) | CA3160334A1 (pl) |
DK (1) | DK3844147T3 (pl) |
ES (2) | ES2940811T3 (pl) |
HR (2) | HRP20220797T1 (pl) |
HU (2) | HUE059403T2 (pl) |
IL (2) | IL292753B2 (pl) |
MX (1) | MX2022005399A (pl) |
NZ (1) | NZ788543A (pl) |
PL (2) | PL3844147T3 (pl) |
PT (2) | PT3844147T (pl) |
WO (2) | WO2021089873A1 (pl) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
HUE059403T2 (hu) | 2019-11-07 | 2022-11-28 | Small Pharma Ltd | Vegyületek |
CN115974757A (zh) | 2020-02-04 | 2023-04-18 | 明德赛特制药公司 | 用于治疗cns病症的作为血清素能致幻剂的赛洛辛衍生物 |
US11332441B2 (en) * | 2020-03-23 | 2022-05-17 | Caamtech, Inc. | Crystalline N-methyl tryptamine derivatives |
AU2021276656A1 (en) | 2020-05-19 | 2022-11-24 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
EP3902541B1 (en) * | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
US20210378969A1 (en) | 2020-06-02 | 2021-12-09 | Small Pharma Ltd. | Therapeutic solid dosage forms |
MX2022014900A (es) * | 2020-06-02 | 2023-03-27 | Small Pharma Ltd | Composiciones terapeuticas que comprenden compuestos n,n-dimetiltriptamina deuterada o parcialmente deuterada. |
US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
WO2021250434A1 (en) | 2020-06-12 | 2021-12-16 | Beckley Psytech Limited | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
EP4122916A1 (en) * | 2021-07-22 | 2023-01-25 | GH Research Ireland Limited | Method for preparing an organic compound |
CA3226980A1 (en) * | 2021-07-22 | 2023-01-26 | GH Research Ireland Limited | Method for preparing a tryptamine derivative. |
US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
EP4159192A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders |
WO2023089132A1 (en) | 2021-11-18 | 2023-05-25 | Small Pharma Ltd | Injectable and inhalable formulations |
WO2023108174A1 (en) * | 2021-12-10 | 2023-06-15 | Terran Biosciences, Inc. | Analogs of 6-methoxy- n, n-dimethyltryptamine |
WO2023147423A1 (en) * | 2022-01-28 | 2023-08-03 | Miralogx Llc | Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders |
US20240101514A1 (en) * | 2022-08-19 | 2024-03-28 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
WO2024079314A1 (en) | 2022-10-13 | 2024-04-18 | Cybin Uk Ltd | Method of administration of a parenteral formulation comprising a psychedelic agent |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4336378A (en) | 1980-04-10 | 1982-06-22 | Sandoz, Inc. | Isoxazolyl indolamines |
JPH06508354A (ja) * | 1991-06-21 | 1994-09-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | トリプタミン類似体、その合成法およびその5−ht↓1様または5−ht↓2受容体作用物質としての使用 |
US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
AU2001266896B2 (en) | 2000-06-16 | 2006-04-06 | Jagotec Ag | Improved injectable dispersions of propofol |
WO2004085392A1 (en) | 2003-03-25 | 2004-10-07 | Faust Pharmaceuticals | Melatonin derivatives and their use for treating neurological dysfunctions |
CN101687788A (zh) | 2006-10-19 | 2010-03-31 | 奥斯拜客斯制药有限公司 | 取代的吲哚 |
WO2008071455A1 (en) | 2006-12-15 | 2008-06-19 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic acyltryptophanols |
CZ302424B6 (cs) * | 2007-06-13 | 2011-05-11 | Zentiva, A. S. | Zpusob prípravy almotriptanu o vysoké cistote |
NZ583192A (en) * | 2007-08-06 | 2012-06-29 | Biotie Therapies Inc | Methods for treating dependence |
US20090076121A1 (en) | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched sumatriptan |
WO2009049030A1 (en) | 2007-10-09 | 2009-04-16 | Triton Biopharma, Llc | Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter |
KR102232221B1 (ko) * | 2013-03-14 | 2021-03-26 | 다트 뉴로사이언스 (케이만) 엘티디. | Pde4 억제제로서 치환된 피리딘 및 피라진 화합물 |
WO2016181414A1 (en) | 2015-05-12 | 2016-11-17 | Council Of Scientific & Industrial Research | Process for the synthesis of ivacaftor and related compounds |
US20200030309A1 (en) * | 2016-09-29 | 2020-01-30 | The Regents Of The University Of California | Compounds for increasing neural plasticity |
CA3052974A1 (en) | 2017-02-09 | 2018-08-16 | CaaMTech, LLC | Compositions and methods comprising a psilocybin derivative |
US20200147038A1 (en) | 2017-04-20 | 2020-05-14 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
WO2019081764A1 (en) | 2017-10-26 | 2019-05-02 | Consejo Superior De Investigaciones Científicas (Csic) | ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS |
WO2019089902A1 (en) | 2017-11-01 | 2019-05-09 | Drexel University | Compounds, compositions, and methods for treating diseases |
EA202192318A1 (ru) | 2019-02-22 | 2021-12-21 | Гх Рисерч Айрленд Лимитед | 5-метокси-n,n-диметилтриптамин (5-meo-dmt) для лечения депрессии |
JP2022522659A (ja) | 2019-02-22 | 2022-04-20 | ジーエイチ リサーチ アイルランド リミテッド | 精神障害の処置における使用のための5-メトキシ-n,n-ジメチルトリプタミン(5-meo-dmt)を含む組成物 |
BR112021016620A2 (pt) | 2019-02-27 | 2021-11-03 | Univ California | Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais |
CA3130767A1 (en) | 2019-02-27 | 2020-09-03 | The Regents Of The University Of California | N-substituted indoles and other heterocycles for treating brain disorders |
GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
HUE059403T2 (hu) | 2019-11-07 | 2022-11-28 | Small Pharma Ltd | Vegyületek |
CN111072492A (zh) * | 2019-11-29 | 2020-04-28 | 浙江工业大学 | 一种合成3,4-二氯-2-氨基-5-氟联苯的方法 |
CN115974757A (zh) | 2020-02-04 | 2023-04-18 | 明德赛特制药公司 | 用于治疗cns病症的作为血清素能致幻剂的赛洛辛衍生物 |
AU2021276656A1 (en) | 2020-05-19 | 2022-11-24 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
WO2021234608A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
US20210378969A1 (en) | 2020-06-02 | 2021-12-09 | Small Pharma Ltd. | Therapeutic solid dosage forms |
US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
EP3902541B1 (en) | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
GB202008961D0 (en) | 2020-06-12 | 2020-07-29 | Beckley Psytech Ltd | Pharmaceutical composition |
BR112023001967A2 (pt) | 2020-08-05 | 2023-02-28 | Univ Basel | Método para induzir um estado psicodélico em um indivíduo, método para induzir um estado psicodélico em um indivíduo com segurança, método para fornecer um tratamento psicodélico de curta duração, método para determinar uma dose de dmt para um indivíduo, método para terapia e método para ajustar um estado psicodélico em um indivíduo em tempo real |
US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
CN115701994B (zh) | 2020-08-28 | 2024-03-08 | 赛本英国有限公司 | 可注射制剂 |
US20220062237A1 (en) | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
CA3194558A1 (en) | 2020-10-02 | 2022-04-07 | Brett J. GREENE | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
-
2020
- 2020-11-09 HU HUE20816376A patent/HUE059403T2/hu unknown
- 2020-11-09 PT PT208163766T patent/PT3844147T/pt unknown
- 2020-11-09 CN CN202080087092.5A patent/CN114829341B/zh active Active
- 2020-11-09 CA CA3160334A patent/CA3160334A1/en active Granted
- 2020-11-09 KR KR1020237033500A patent/KR20230142817A/ko not_active Application Discontinuation
- 2020-11-09 NZ NZ788543A patent/NZ788543A/en unknown
- 2020-11-09 CA CA3160337A patent/CA3160337C/en active Active
- 2020-11-09 JP JP2022526074A patent/JP7423131B2/ja active Active
- 2020-11-09 EP EP20816375.8A patent/EP3873883B1/en active Active
- 2020-11-09 PT PT208163758T patent/PT3873883T/pt unknown
- 2020-11-09 ES ES20816375T patent/ES2940811T3/es active Active
- 2020-11-09 PL PL20816376.6T patent/PL3844147T3/pl unknown
- 2020-11-09 JP JP2022526073A patent/JP7422473B2/ja active Active
- 2020-11-09 AU AU2020381103A patent/AU2020381103B2/en active Active
- 2020-11-09 CN CN202080087091.0A patent/CN114829340B/zh active Active
- 2020-11-09 AU AU2020378647A patent/AU2020378647B2/en active Active
- 2020-11-09 BR BR112022008919A patent/BR112022008919A2/pt not_active Application Discontinuation
- 2020-11-09 KR KR1020227018623A patent/KR20220082092A/ko not_active IP Right Cessation
- 2020-11-09 IL IL292753A patent/IL292753B2/en unknown
- 2020-11-09 WO PCT/EP2020/081503 patent/WO2021089873A1/en unknown
- 2020-11-09 DK DK20816376.6T patent/DK3844147T3/da active
- 2020-11-09 PL PL20816375.8T patent/PL3873883T3/pl unknown
- 2020-11-09 ES ES20816376T patent/ES2920681T3/es active Active
- 2020-11-09 MX MX2022005399A patent/MX2022005399A/es unknown
- 2020-11-09 HR HRP20220797TT patent/HRP20220797T1/hr unknown
- 2020-11-09 HR HRP20230281TT patent/HRP20230281T1/hr unknown
- 2020-11-09 WO PCT/EP2020/081502 patent/WO2021089872A1/en active Application Filing
- 2020-11-09 HU HUE20816375A patent/HUE061482T2/hu unknown
- 2020-11-09 EP EP22214748.0A patent/EP4180037A1/en active Pending
- 2020-11-09 EP EP20816376.6A patent/EP3844147B1/en active Active
-
2021
- 2021-08-26 US US17/412,828 patent/US11643390B2/en active Active
-
2022
- 2022-05-03 IL IL292754A patent/IL292754A/en unknown
- 2022-05-06 US US17/662,261 patent/US11578039B2/en active Active
-
2023
- 2023-01-10 US US18/152,465 patent/US20230167056A1/en active Pending
- 2023-03-31 US US18/193,866 patent/US20230250059A1/en active Pending
- 2023-11-30 JP JP2023202672A patent/JP2024028798A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL292753A (en) | compounds | |
IL289463A (en) | Agonist-gipr compounds | |
GB201905721D0 (en) | Compounds | |
GB201916915D0 (en) | Compounds | |
GB201910305D0 (en) | Compounds | |
GB201908536D0 (en) | Compounds | |
GB201908171D0 (en) | Compounds | |
GB201910304D0 (en) | Compounds | |
GB201908095D0 (en) | Carboxy-MIDA-boronate compounds | |
GB201919205D0 (en) | Compounds | |
GB201918761D0 (en) | Compounds | |
GB201918424D0 (en) | Compounds | |
GB201917895D0 (en) | Compounds | |
GB201917893D0 (en) | Compounds | |
GB201917891D0 (en) | Compounds | |
GB201916847D0 (en) | Compounds | |
GB201916597D0 (en) | Compounds | |
GB201916595D0 (en) | Compounds | |
GB201916572D0 (en) | Compounds | |
GB201916142D0 (en) | Compounds | |
GB201914208D0 (en) | Compounds | |
GB201913633D0 (en) | Compounds | |
GB201913541D0 (en) | Compounds | |
GB201912850D0 (en) | Compounds | |
GB201911848D0 (en) | Compounds |